SecBot SecBot
8-K ·Filed Jun 29, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizonmonths Processed4mo ago SEC0001104659-26-078865
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor future 8-K filings for actual equity grant details under the new plan. The approval is routine and does not change the company's near-term outlook.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$541.83
T+0 close · Jun 29, 2026 · via day close
Latest settled
−9.67%
T+60 · $489.42
Vs SPY
−12.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $541.83entry
  2. T+1 · 5mo ago +0.98%α +1.12% · $547.15
  3. T+5 · 4mo ago +1.00%α +0.40% · $547.25
  4. T+20 · 4mo ago −2.56%α −1.54% · $527.94
  5. T+60 · 8w ago −9.67%α −12.49% · $489.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

United Therapeutics shareholders approved the 2026 Stock Incentive Plan at the annual meeting, adding 1,500,000 new shares plus the remaining 2,413,730 shares from the prior plan to the equity compensation reserve. All 12 director nominees were elected, and the advisory say-on-pay resolution passed with 97% support. This is a routine governance filing with no material financial impact.

Key Facts

  • Shareholders approved the 2026 Stock Incentive Plan with 25,872,075 votes for and 10,070,290 against (72% of votes cast in favor).
  • The plan adds 1,500,000 new shares plus 2,413,730 shares remaining from the prior plan, with potential additional shares from forfeited awards.
  • All 12 director nominees were elected with strong support (lowest 'for' vote was 32,342,983 for Christopher Causey).
  • Advisory vote on executive compensation passed with 35,152,059 votes for (97% of votes cast).
  • Ernst & Young LLP was ratified as independent auditor for 2026 with 35,753,887 votes for.

Financial Impact

No immediate financial impact; the plan authorizes future equity grants but no specific grants were made in this filing.

dilution

Risk Factors

  • Potential future dilution from equity grants under the new plan, though the 1,500,000 new shares represent approximately 3% of outstanding shares.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-078865
Document: tm2619258d1_8k.htm0001104659-26-078865
Document: 0001104659-26-078865-index-headers.html0001104659-26-078865
Document: 0001104659-26-078865-index.html0001104659-26-078865
Document: 0001104659-26-078865.txt0001104659-26-078865

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens Wed (9h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026